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MEDICARE PRESCRIPTION ‘DRUG LEGISLATION: 
What It Means for Rural Beneficiaries 
 
EXECUTIVE SUMMARY 
 
Congress is currently debating legislation that would not only add a prescription drug benefit to 
Medicare but create an unprecedented role for private health insurers in delivering all Medicare 
services.  Such changes would have profound effects on the 41 million people covered by 
Medicare -- particularly the one in four who lives in rural America.  Previous studies have shown 
that rural beneficiaries have different health care needs and delivery systems than their urban 
counterparts.  Indeed, the bills that passed the House and Senate address payments to rural 
hospitals and other providers.  However, less attention has been paid to the rural beneficiary 
implications of the prescription drug benefit and private plan reforms included in the Medicare 
legislation.  This study does so, through new data analysis and synthesis of existing information.   
 
The results of this study underscore the unique challenges that face Medicare’s 9 million rural 
beneficiaries today and under the Medicare proposals under consideration.  New analysis shows 
that rural beneficiaries are, relative to urban beneficiaries, older, sicker, and poorer and have a 
greater need for a Medicare drug benefit.  They are nearly twice as likely to lack any type of 
insurance coverage for prescription drugs.  However, the design of a Medicare prescription drug 
benefit is critical to ensuring that the unique needs of Medicare’s rural beneficiaries are met.  
Rural beneficiaries would be disadvantaged by a Medicare prescription drug benefit that has 
weak protections for low-income beneficiaries – or excludes them altogether.  Their higher 
incidence of chronic illnesses like arthritis and heart disease would leave them vulnerable to 
higher prescription drug cost sharing and premiums if private insurers rather than Medicare were 
to define the benefit.  In addition, a prescription drug benefit that relies exclusively on private 
insurers could create serious access problems for rural beneficiaries.  This study shows that 
private insurers have proven unreliable in rural areas: they are less likely to serve rural areas, and 
when they do, they are less likely to maintain service over a sustained period of time.  Finally, 
reforms outside the addition of a prescription drug benefit could exacerbate the current inequities 
caused by Medicare funding of supplemental health benefits only through private plans.  Not 
only do rural beneficiaries have less access to subsidized benefits through private plans, but they 
would fund these benefits through higher Medicare premiums.  The report concludes by 
recommending that stronger protections for low-income and sicker beneficiaries, a more stable 
prescription drug delivery system, and a more equitable allocation of Medicare subsidies for 
supplemental benefits – rather than concentrating them in private plans -- would make the 
ultimate Medicare legislation more responsive to rural beneficiaries’ circumstances.   
 
Highlights of the study include:  
 
Greater Need for a Medicare Drug Benefit in Rural America 
 
• Lower rate of prescription drug coverage:  The proportion of rural beneficiaries lacking 
drug coverage is nearly double that of urban beneficiaries.  Nearly one in three (31%) of rural 
Medicare beneficiaries had no prescription drug coverage in 2000, compared to 18 percent of 
urban beneficiaries.   
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o This disparity is greater for sicker beneficiaries: among those in fair to poor health, 
rural beneficiaries are over 70 percent more likely to lack drug coverage than urban 
beneficiaries (28.8 versus 16.2%).   
 
o The oldest rural beneficiaries are least likely to have drug coverage despite their 
greater need for medications.  About 37 percent of rural beneficiaries age 85 and 
older lacked drug coverage, compared to 23 percent of the oldest urban beneficiaries. 
 
• Much lower Medicare managed care coverage:  Medicare implicitly subsidizes 
prescription drug coverage by paying Medicare managed care plans more than their costs of 
providing Medicare’s core benefits.  However, rural beneficiaries have less access to such 
plans.  This helps explain why only 3 percent of rural beneficiaries received drug coverage 
through these plans compared to 18 percent of urban beneficiaries.  
 
• Higher out-of-pocket costs:  Rural Medicare beneficiaries’ average out-of-pocket spending 
on prescription drugs is about 25 percent higher than that of urban beneficiaries.  This 
difference reflects the much-lower rates of supplemental prescription drug coverage among 
rural beneficiaries rather than a greater use of medications. 
 
Implications of Prescription Drug Benefit Designs on Rural Beneficiaries 
 
• Fewer eligible for the drug benefit:  Rather than creating a universal benefit, the Senate bill 
would exclude from the Medicare prescription drug benefit those beneficiaries who also are 
enrolled in Medicaid.  Due to their lower average income, a greater proportion of rural 
beneficiaries would not qualify for the Medicare benefit (12.4 rural versus 10.5%).  Applied 
to 2006 projections, this could mean 1.7 million rural beneficiaries are prohibited from 
accessing the Medicare benefit.  This means that the lowest-income and sickest Medicare 
beneficiaries could get a different, and ultimately, lesser benefit as states, which share in 
Medicaid costs, scale back coverage due to costs.  Not only do more “dual eligibles” live in 
rural areas, but their average drug costs are higher compared to that of urban beneficiaries.  
Predominantly rural states would therefore face a disproportionately larger cost burden.  
 
• Less relief from high out-of-pocket drug costs:  Both bills, to fit within budget constraints, 
would subsidize only about one-third of total prescription drug costs.  Because over half of 
rural beneficiaries without drug coverage also have low income (below 150 percent of 
poverty or about $13,500 per single), extra assistance would be needed to eliminate cost as a 
barrier to needed medicines for rural beneficiaries.   
 
• Potentially higher drug cost sharing and premiums:  Neither proposal includes a defined 
Medicare benefit.  Instead, they would allow private plans to set cost sharing for covered 
drugs, within bounds, and determine beneficiary premiums.  Since rural beneficiaries are 
more likely to be in fair to poor health (32.5 versus 28.9%) and to have chronic diseases like 
diabetes and arthritis, they could be vulnerable to higher cost sharing and premiums as 
private plans try to avoid their enrollment and cover their costs. 
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Implications of Promotion of Private Plans on Rural Beneficiaries 
 
• Access uncertain:  The Senate bill would rely on, and the House bill would require, private 
insurers to deliver the prescription drug benefit.  Yet, studies have found that, even with 
payment rates well above the average accosts of traditional Medicare, private plans are much 
less likely to serve rural seniors.   
 
• More unstable in rural areas:  Even in rural areas that private plans have opted to served, 
private plan participation has been more volatile than in urban areas.  Among beneficiaries 
with access to private plans, rural residents were four times more likely than urban 
beneficiaries to lack a private plan option that was available for the past three years.   
 
o Loss of private health plans was a greater cause of instability in rural than urban 
areas, accounting for nearly half of volatility (and 33% of urban volatility). 
 
o In five predominantly rural states, no single private plan offered and enrolled 
Medicare beneficiaries for the entire 2001-03 period.  These states were Alaska, 
Maine, Montana, South Dakota and Vermont.  In addition, Delaware, New 
Hampshire and South Caroline lacked a stable private plan option in their rural 
counties during the period. 
 
• Exacerbates benefit inequity:  Both proposals would continue the current system that 
allows Medicare overpayments to private plans to be used to subsidize extra benefits for 
enrollees.  In addition, the legislation would increase private plan payment rates, costing 
Medicare $6 to $8 billion over 10 years, according to the Congressional Budget Office.  
Under the Administration’s projected enrollment, this cost could be up to 4 times higher, or 
$32 billion over the period.  This is on top of the relief that private plans would get with the 
passage of a Medicare-subsidized prescription drug benefit.   
 
o Increased private plan funding and, thus, subsidized benefits would most likely 
benefit urban beneficiaries, given patterns in the past. 
 
o The increased private plan funding could instead be used to either improve benefits 
for all Medicare beneficiaries or eliminate the bills’ increases in home health and lab 
copayments and the Part B deductible.  These cost sharing increases would 
disproportionately affect rural beneficiaries given their lower average income and 
already-higher out-of-pocket cost burden.  Compared to urban beneficiaries, rural 
beneficiaries’ out-of-pocket spending on Medicare-covered provider services, 
outpatient hospital and inpatient hospital care is 10, 30 and 80 percent higher 
respectively.   
 
• Penalizes those staying in traditional Medicare:  As with any increase in Medicare Part B 
costs, the House- and Senate-proposed increases in payments to private plans would increase 
beneficiary premiums.  This means that rural beneficiaries would pay higher premiums to 
subsidize private plans even if they lack access to the extra benefits offered by those plans.     
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o The House “premium support” provision would exacerbate this premium increase by 
changing the structure of Medicare financing beginning in 2010.  The government 
would, in areas where private plans participate, cap its liability for costs, even for 
traditional Medicare.  Although rural areas are less likely to have private plan 
participation and thus premium support, the premium impact would be greater if 
private plans emerged.  The proposal could cause premiums to rise by $24 a month if 
fully implemented in 2010, an amount that would represent a larger percentage of 
rural beneficiaries’ lower average Social Security checks.   
 
As policy makers move toward final passage of this legislation, a number of changes could be 
made to the pending legislation to ensure that it protects and strengthens Medicare for rural 
beneficiaries.  First, given the age, health, and income profile of rural beneficiaries, stronger 
protections for low-income and sicker beneficiaries should be considered.  Making Medicare 
accessible for all beneficiaries, including the lowest-income seniors, as is done in the House bill, 
would help the larger proportion of rural beneficiaries who are enrolled in Medicaid and thus be 
disqualified under the Senate plan.  However, the Senate bill’s prescription drug subsidies for 
those above Medicaid eligibility limits are more generous than the House bill’s.  This assistance 
would be critical since near-poor rural beneficiaries are less likely to have prescription drug 
coverage and more likely to spend a high percentage of their income on prescriptions.  In 
addition, since rural beneficiaries are more likely to be in poor health, defining the benefit would 
prevent private insurers from avoiding or cost shifting to rural seniors through high copayments 
on expensive drugs or high premiums.   
 
Second, Congress should consider a more stable delivery system for the prescription drug 
benefit.  The experience of the Medicare+Choice program promises greater private plan scarcity 
and volatility in rural versus urban areas.  This suggests that rural beneficiaries should be given a 
choice of receiving the drug benefit through private insurers or a stable, non-risk bearing private 
plan.  Short of that, defining larger service areas for prescription drug plans, ensuring that there 
is a “fallback” system in place if private plans do not serve rural areas, having multi-year 
contracts for plans, and letting fallback plans stay in areas vulnerable to under-service could 
lessen the volatility in prescription ding coverage that is likely to occur in rural America.   
 
Third, Medicare subsidies for supplemental benefits should be allocated so that all beneficiaries, 
regardless of where they live or which delivery system they choose, receive the same level of 
Medicare assistance.  Rather than exacerbating the benefit inequities caused by overpayments in 
the Medicare managed care system, the final legislation should use the proposed funding 
increase for this system to improve benefits for all beneficiaries or eliminate the proposed 
increases in cost sharing.  Finally, the House bill’s premium support proposal, while less likely to 
affect rural areas, would create a greater cost burden on rural versus urban beneficiaries given 
their lower income and already-high spending on Medicare cost sharing.  It should be 
reconsidered.  All together, these recommendations are intended to contribute to the goal of 
ensuring that the final Medicare prescription drug legislation meets the needs of this vulnerable 
group of Americans. 
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MEDICARE PRESCRIPTION DRUG LEGISLATION: 
WHAT IT MEANS FOR RURAL BENEFICIARIES 
 
INTRODUCTION 
 
After years of debate, the U.S. Congress has reached a key stage in the effort to add a 
prescription drug benefit to the Medicare program.  Both the House and Senate passed legislation 
in June 2003, with the intention of enacting a Medicare prescription drug benefit this fall.  Few 
policy makers, fewer experts, and virtually no seniors deny that this action is long overdue.  The 
health and economic consequences of this major gap in Medicare’s benefit package are well 
documented.  However, the costs and complexities of providing a meaningful drug benefit to 
over 40 million people with significant medication needs have made it hard to develop consensus 
around proposals.  In addition, the extent to which prescription drug legislation includes reform 
to the underlying Medicare program has been an obstacle.  The House and Senate overcame 
these challenges to pass legislation, but they did so with different bills that may be difficult to 
merge.  In addition, myriad other issues have surfaced in this complex legislation, ranging from 
the large, unintended effects that the proposals may have on retiree coverage to who defines the 
term “therapeutic class” for determining what drugs must be covered under the drug benefit.  
 
A key question in the Medicare debate is the implication of the legislation on rural beneficiaries.  
Organization such as the National Rural Health Association1 and the Rural Policy Research 
Institute (RUPRI)2 have issued criteria to be used in developing legislation to meet rural 
beneficiaries’ needs.  In addition, a Presidential Commission presented a report to President 
Bush on guidance for Medicare reform in 2001.3  Indeed, the legislation passed in both chambers 
of Congress has provisions aimed at addressing rural needs.  Both bills include a set of policies 
that would increase various provider payments in rural areas.  Both bills include explicit 
provisions to ensure that rural beneficiaries have access to pharmacies in the new prescription 
drug benefit.  And the Senate proposal would direct various groups to monitor the impact of the 
legislation on rural areas.4   
 
Despite this interest, little analysis to date has focused on what these House- and Senate-passed 
bills would mean for rural beneficiaries.  This study offers such an assessment.  Specifically, it 
provides new information on the need for a prescription drug benefit among rural beneficiaries, 
discusses the implications of the current proposals on rural beneficiaries, and identifies changes 
to the proposals that would reduce potential disparities in the treatment of rural residents.  The 
report focuses on issues affecting beneficiaries’ access to benefits and costs.  As such, it does not 
address quality, overall drug pricing issues, and the rural health care provider payment 
provisions in the bills.  It does assess the Medicare managed care changes, but does so from the 
viewpoint of its effect on access to supplemental benefits.  The report is divided into five 
sections: the greater need for a Medicare drug benefit in rural America; the proposed Medicare 
legislation; the implications of the prescription drug benefit designs on rural beneficiaries; the 
implications of the proposed promotion of private plans on rural beneficiaries, and a discussion 
and recommendations section.  The methodology is described in the appendix.  The research aim 
is to provide policy makers, the public, and rural beneficiaries with information that could be 
used to ensure that the final Medicare prescription drug bill meets the needs of this vulnerable 
group of Americans. 
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GREATER NEED FOR A MEDICARE DRUG BENEFIT IN RURAL AMERICA 
 
The elderly who live in rural America are often considered symbolic of the nation’s past:  former 
farmers, teachers, World War II veterans and others whose efforts paved the way for the current 
generation.  In addition to the rural elderly, Medicare covers certain rural people with 
disabilities, who are a larger fraction of the rural than urban beneficiary population.  Nine million 
Medicare beneficiaries live in rural America. Representing nearly one in four Medicare 
beneficiaries nationwide, rural beneficiaries comprise 60 percent or more of all beneficiaries in 
seven states (ID, IA, ME, MS, MT, SD, WY) (see Appendix).  And, as younger people move out 
of rural areas and the baby boom generation begins to retire, rural beneficiaries’ representation 
will grow.5   In addition to their demographic importance, rural Medicare beneficiaries face 
special challenges to their health, access to health services, and economic well-being.  Compared 
to urban beneficiaries, rural Medicare beneficiaries are:  
 
• Older:  A larger proportion of the rural seniors are age 85 or older (7.8 versus 7.0%).  In this 
age 85+ group, rural residents are more likely to be women (68.1 versus 64.5%) and to live 
alone (63.1 versus 60.5%). 6 
 
• Sicker:  Rural Medicare beneficiaries are more likely to report fair to poor health than urban 
beneficiaries.  This does not just reflect the greater proportion of rural beneficiaries with 
disabilities.  In all age groups, rural seniors are more likely to be in worse health. 7  Rural 
beneficiaries, as with younger rural residents, are also more likely to have a chronic illness.8   
 
• Poorer:  Compared to urban seniors, rural seniors have lower average income, higher 
poverty rates, and a greater reliance on Social Security income. 9   
 
Previous studies have also found that rural Medicare beneficiaries have a greater need for a 
prescription drug benefit. 10  This study provides new analyses from the 2000 Medicare Current 
Beneficiary Survey (MCBS) that compares rural and urban beneficiaries on their coverage and 
spending.  The results are described below.   
 
Lower rate of prescription drug coverage.  The proportion of rural beneficiaries lacking any 
prescription drug coverage is nearly double 
that of urban beneficiaries.  Nearly one in 
three (31% of) rural Medicare beneficiaries 
had no prescription drug coverage in 2000, 
compared to 18 percent of urban beneficiaries 
(Figure 1).   
Rural Medicare Beneficiaries More 
Likely to Lack Drug Coverage
Proportion of Medicare Beneficiaries Without Any 
Type of Drug Coverage, 2000
18%
31%
Urban Rural
Source:  Analysis of 2000 Medicare Current Beneficiary Survey; excludes institutionalized beneficiaries
Figure 1
 
This disparity is greater for those in fair to 
poor health:  amongst them, rural 
beneficiaries are over 70 percent more likely 
to lack drug coverage than urban beneficiaries 
(28 versus 16%) (Appendix).   
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The oldest rural beneficiaries are least likely to 
have drug coverage despite their greater need 
for it.  About 37 percent of rural beneficiaries 
age 85 and older lacked drug coverage, 
compared to 23 percent of the oldest urban 
beneficiaries (Figure 2).  This deterioration of 
coverage among the oldest rural residents may 
reflect their lack of access to sources of 
coverage like employer-sponsored retiree health 
plans and Medigap, and their lower 
participation in Medicare Health Maintenance 
Organizations (HMOs) when given the option. 
Drug Coverage Declines With Age, 
Especially Among Rural Beneficiaries
Proportion of Medicare Beneficiaries by Age Without 
Any Type of Drug Coverage, 2000
17% 18%
23%26%
31%
37%
< 65 65-84 85+
Urban Rural
Source:  Analysis of 2000 Medicare Current Beneficiary Survey; excludes institutionalized beneficiaries
Figure 2
 
Much lower Medicare managed care 
coverage.  Historically, Medicare has 
subsidized prescription drug coverage by 
allowing private plans to use excess Medicare 
payments to pay for such coverage.  However, 
rural beneficiaries have less access to such 
plans.  This helps explain why only about 3 
percent rural beneficiaries received coverage 
through Medicare HMOs, compared to 18 
percent of urban beneficiaries (Figure 3).  Rural 
seniors are also far less likely to have drug 
benefits from former employers, leaving them 
with few options except to buy coverage on 
their own through Medigap.   
Different Sources of Prescription 
Drug Coverage
Distribution of Medicare Beneficiaries’ 
Drug Coverage, 2000
Rural Beneficiaries
Medicaid, 
12%Other, 12%
Medigap, 
15%
Former 
Employer, 
27%
Medicare 
HMO, 3%
NO 
Coverage, 
31%
Source:  Analysis of 2000 Medicare Current Beneficiary Survey; excludes institutionalized beneficiaries; mutually exclusive categories.
Urban Beneficiaries
Medicaid, 
11%
Other, 10%
Medigap, 
9%
Former 
Employer, 
34%
Medicare 
HMO, 18%
NO 
Coverage, 
18%
Figure 3
 
 
Rural Medicare Beneficiaries Pay 
More Out-of-Pocket for 
Prescription Drugs
Average Annual Out-of-Pocket Spending for 
Prescription Drugs, 2000
$423
$526
Urban Rural
Source:  Analysis of 2000 Medicare Current Beneficiary Survey; excludes institutionalized beneficiaries
Figure 4 Higher out-of-pocket costs. Rural Medicare 
beneficiaries’ average annual out-of-pocket 
spending on prescription drugs is about 25 
percent higher than that of urban 
beneficiaries -- $526 versus $423 (Figure 4).  
While their out-of-pocket spending is higher, 
rural beneficiaries’ total prescription drug 
spending is, actually, slightly lower than that 
of urban beneficiaries, despite their higher 
age and worse health.  The most likely cause 
of this discrepancy is the much lower 
supplemental prescription drug coverage 
among rural beneficiaries.   
 
Rural beneficiaries’ combination of poor health, low levels of drug coverage, and low income 
create particular problems in gaining access to needed medications.  A study of rural seniors in 
North Carolina found that 17 percent bought only part of the recommended prescription, and 15 
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percent took less medicine than prescribed.11  Another study found that rural beneficiaries were 
60 percent more likely than urban beneficiaries to forgo necessary prescriptions due to cost.12   
 
PROPOSED MEDICARE LEGISLATION 
 
Both Chambers of Congress passed legislation before the July 4th recess that would, most 
notably, add a prescription drug benefit to Medicare.  By a one-vote margin (216 to 215), the 
House of Representatives passed H.R. 1, “Medicare Prescription Drug and Modernization Act of 
2003.”  This legislation includes a standard prescription drug benefit that has a $250 deductible, 
20 percent coinsurance through $2,000 in total costs, and an annual limit on out-of-pocket 
spending of $3,500 in 2006.  The Congressional Budget Office (CBO) estimates that the 
benefit’s average premium would be $35.50 per month. 13  Later on the same day (June 27, 
2003), the Senate voted 76 to 21 in favor of S. 1, “Prescription Drug and Medicare Improvement 
Act of 2003.”  Its standard drug benefit in 2006 would have a $275 deductible, 50 percent 
coinsurance through $4,500 in total spending, and 10 percent coinsurance once annual out-of-
pocket spending has exceeded $3,700.  Its premiums are estimated to average $34 per month.  
The conference committee to reconcile differences in these bills was appointed on July 14, and 
adopted a schedule that would conclude its work in September 2003.14  
 
The House and Senate proposals are similar in a number of respects.15  Both give private insurers 
the primary role in delivering the drug benefit.  To facilitate insurer participation, the proposals 
would let them charge cost sharing that is different than the standard benefit, described above, 
within limits.  Both bills would create a prescription drug discount card program aimed at 
reducing prices before the drug benefit is implemented in 2006.  Both are estimated to cost about 
$400 billion over 10 years.16  In addition to the creating a drug benefit, the bills include 
provisions on improving access to generic drugs, reducing payments for drugs already covered 
by Medicare, and re-importing drugs from other countries for sale in the U.S.  They would 
reform Medicare’s regulatory structure, create a new agency, and change numerous provider 
payment rates in the traditional program.  Over the 2004-13 period, the bills would increase 
payments to rural health care providers by about $25 billion; increase Medicare cost sharing by 
$13 billion (House) and $29 billion (Senate), and increase payments to Medicare HMOs and 
preferred provider organizations (PPOs) by about $8 billion (without the Senate 
demonstration).17   
 
Important differences exist as well.  The House bill would exclusively rely on private insurers to 
deliver the drug benefit, not authorizing the use of non-risk bearing “fallback” plans in 
underserved areas, as is done in the Senate bill.  In addition, the bills include very different 
policies regarding low-income beneficiaries.  The Senate bill would prohibit low-income 
beneficiaries also eligible for Medicaid from enrolling in the Medicare drug benefit.  The House 
bill would provide no financial assistance for low-income seniors above Medicaid eligibility 
limits for costs in the Medicare benefit “gap”.  Outside of the drug benefit, the House bill 
includes a premium support provision, called “FEHBP-style competitive reforms” that, 
beginning in 2010, would cap Medicare’s contribution to all plans, including the traditional 
program in areas with two or more plans.  The hundreds of pages of legislation contain numerous 
other differences as well. 
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IMPLICATIONS OF PRESCRIPTION DRUG BENEFIT DESIGNS ON RURAL 
BENEFICIARIES 
 
In many respects, rural beneficiaries are no different than urban beneficiaries in their need for a 
universal, affordable, reliable prescription drug benefit in Medicare.  Advocates and experts have 
examined these bills from this broader perspective.18  This study focuses on those aspects of the 
proposals that would have a unique or disproportionate affect on those who live in rural America. 
To do so, it draws on new analysis of the current differences between rural and urban 
beneficiaries on a number of dimensions.  Three major issues are identified, described below.  
 
Fewer eligible for the drug benefit.  Rather than creating a universal benefit, the Senate bill 
would exclude from the Medicare prescription drug benefit those beneficiaries who also qualify 
for Medicaid (called “dual eligibles”).  Their lower average income means that a greater 
proportion of rural beneficiaries are dual eligilbes and would not qualify for the Medicare benefit 
(12.4 versus 10.5%).19  Applying this 
relationship to the Congressional Budget 
Office’s estimates of the number of dual 
eligibles in 2006, an estimated 1.7 million 
low-income rural beneficiaries would be 
prohibited from enrolling in the Medicare 
benefit.20  This could result in worse 
prescription drug coverage for the lowest-
income seniors.  Since states share in 
Medicaid costs and have options to reduce 
Medicaid drug coverage, they will likely do so 
as the baby boom generation retires, 
increasing Medicaid long-term care costs as 
well as drug costs.   
Rural Medicare-Medicaid 
Beneficiaries More Costly 
Total Prescription Drug Spending of Non-
Institutionalized Dual Eligibles, 2000
$1,660$1,595
Urban Rural
Source:  Analysis of 2000 Medicare Current Beneficiary Survey; excludes institutionalized beneficiaries
Figure 5
 
Not only do more dual eligibles live in rural areas, but their average drug costs are higher 
compared to their urban counterparts (Figure 5).  This suggests that predominantly rural states 
would face a disproportionately larger cost burden if the final legislation requires states to 
continue providing drug coverage for poor Medicare beneficiaries through Medicaid.21  
 
Less relief from high out-of-pocket drug costs.  Both bills, to fit within budget constraints, 
would subsidize only a fraction of total prescription drug costs.  Consequently, average 
beneficiaries would still pay for two-thirds of their 
current drug costs through premiums and cost sharing 
(Table 1).  This level of out-of-pocket spending could 
prevent some seniors from purchasing needed drugs, 
especially if they have lower income.  Both bills 
provide extra assistance for people with lower 
income.  The Senate invests considerably more in this 
assistance, eliminating the benefit “gap” for 
beneficiaries with income below 160 percent of the 
poverty level ($19,200 per couple).   
Table 1. Average Medicare Beneficiary 
Payments for Standard Prescription Drug 
Coverage in the H.R. 1 and S. 1, 2006 
 
 House   Senate 
Avg Total Costs*:  $3,081  $3,127 
Annual Premiums*: $426  $408 
Deductible: $250  $275 
Coinsurance: $350  $1,426 
Gap: $1,081  -- 
Total Out-of-Pocket: $2,107  $2,109 
As % of Total Costs: 68%  67% 
 
* CBO, 7/03 
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However, even with these protections, some 
low-income beneficiaries could still pay up to 
15 percent of their income on out-of-pocket 
drugs cost sharing and premiums.22  Adopting 
strong low-income protections is especially 
important for rural beneficiaries.  Rural 
beneficiaries have lower income than urban 
beneficiaries generally, and over half of rural 
beneficiaries without prescription drug 
coverage have low income (Figure 6).  While 
generally improving the standard benefits in 
both bills would assist rural beneficiaries, 
targeting any additional resources at 
strengthening the low-income provisions would probably result in a relatively greater reduction 
in out-of-pocket costs for rural beneficiaries. 
Rural Medicare Beneficiaries 
Have Lower Income
Percent of Medicare Beneficiaries With Income < 150 
Percent of Poverty, 2000
Source:  Analysis of 2000 Medicare Current Beneficiary Survey; excludes institutionalized beneficiaries.  
Poverty is equal to about $9,000 for a single person, $12,000 for a couple in 2003.
40%
48%46%
53%
Urban Rural
All No Drug Coverage
Figure 6
  
Potentially higher drug cost sharing and premiums.  The proposals do not include a defined 
Medicare benefit.  Instead, they would create “standard benefits” that serve as yardsticks for 
insurers that want to change the cost sharing.  For example, under the House bill, a private 
insurer could eliminate the gap by charging 47.8 percent coinsurance on all drug costs above the 
deductible but below the catastrophic limit.23  In addition, an insurer could vary beneficiary 
copays across types of drugs.  For instance, it could charge very high copay on an expensive but 
rare medication and a slightly lower copay on a less expensive but more common drug and still 
satisfy the bills’ requirements.24  The copayment structure could be a way for drug insurers to 
avoid sicker enrollees.  Beyond the variable cost sharing, there would be no standard premium 
for drug coverage, as in the current Part B program.  Medicare would adjust premium subsidies 
to plans for drug price (not utilization) variation and risk of enrollees and provide reinsurance.  
However, private plans would determine what beneficiaries pay and this could be higher for rural 
beneficiaries if their higher costs are not fully accounted for in the Medicare payments.   
 
Rural beneficiaries would be particularly affected by the potential for higher cost sharing and 
premiums for sicker beneficiaries in the absence of a defined benefit.  Rural beneficiaries are 
more likely to be in fair to poor health (32 
versus 29%) and to have chronic diseases like 
cancer, diabetes and arthritis.  In addition, as 
with all rural beneficiaries, chronically ill 
rural beneficiaries are more likely to lack any 
type of drug coverage (Appendix).  For 
example, a rural senior with cancer is nearly 
twice as likely as an urban senior to lack drug 
coverage (30 versus 17 percent) (Figure 7).  
This coverage gap exists among those with 
Alzheimer’s disease, chronic lung disease, 
mental disorders, and stroke. 
Medicare Beneficiaries With Chronic
Illnesses Lacking Drug Coverage 
Proportion of Medicare Beneficiaries with the 
Condition Without Drug Coverage, 2000
17% 17% 16% 17%
30% 29% 29%
26%
Cancer Arthritis Alzheimer's
Disease
Mental Illness
Urban Rural
Source:  Analysis of 2000 Medicare Current Beneficiary Survey; excludes institutionalized beneficiaries.  Not mutually exclusive
Figure 7
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IMPLICATIONS OF PROMOTION OF PRIVATE PLANS ON RURAL BENEFICIARIES 
 
Both Medicare proposals under consideration would, to different degrees, promote the role of 
private insurers in Medicare.  The Senate bill would provide preferences to, and the House bill 
would require, that the new prescription drug benefit be delivered only through private insurers.  
The Senate bill, recognizing that private plans may not serve some, particularly rural areas, has a 
“fallback” provision that would allow Medicare to contract with organizations other than private 
insurers to deliver the drug benefit in rare circumstances.  The House has no such provision.25  In 
addition, both Medicare proposals under consideration would increase payments to and create 
new systems of paying Medicare HMOs and other private plans.  Medicare managed care plans 
have typically used excess Medicare payments to subsidize supplemental benefits.  This would 
increase under the legislation that would increase private plans rates and would require that 
private plans offer supplemental benefits like a limit on beneficiaries’ annual out-of-pocket costs.   
 
To assess the impact of these policies on rural beneficiaries, this study: (1) reviews evidence on 
rural beneficiaries’ access to private plans; (2) provides new information on the recent stability 
of private plan participation in rural areas; and (3) discusses the implications of the proposed 
changes to Medicare’s private plan system and the traditional program’s premium on rural 
beneficiaries.   
 
Lower access to private plans.  To date, no major employer or insurer has paid for prescription 
drug coverage through a separate, risk-based prescription drug insurer.  This raises questions 
about private insurers’ interest in and ability to provide a prescription drug benefit to Medicare 
beneficiaries in general, let alone rural beneficiaries.  The experience in Medicare managed care 
plans offers lessons for the challenges facing a system that relies on private insurers.  Despite 
years of effort, a much lower proportion of rural Medicare beneficiaries have access to private 
plans for the delivery of health benefits.  In 2003, 13 percent of rural beneficiaries have access to 
a Medicare coordinated care plan compared to 72 percent of urban beneficiaries, according to the 
Medicare Payment Advisory Commission (MedPAC).  When talking into account other types of 
private plans like private fee-for-service, 61 percent of rural beneficiaries have access to a 
private plan compared to 85 percent of urban beneficiaries – a smaller difference, but still one 
that leaves nearly 30 percent fewer rural beneficiaries with a private plan option.26  It is 
important to note that the additional private plan options available to rural beneficiaries rarely 
provide supplemental benefits like prescription drugs.  This lack of managed care plans in rural 
areas is generally attributed to three factors:  
the challenges in developing provider 
networks, the low density of the population, 
and the inability to gain savings by reducing 
utilization, which, despite rural seniors’ worse 
health status, is not high relative to most 
standards.27   
Rural Beneficiaries Have Less Stable 
Private Plan Options
Medicare Beneficiaries in Counties That Had Enrollment In 
Private Plans in 2001, 2002 and/or 2003
6%
24%
Urban Rural
Beneficiaries Without Access
to Stable Plan (At Least One
Plan Stays In Area for 3 Years)
Source:  Analysis of 2001-03 CMS Quarterly Plan Data for June 2001, 2002 and 2002.  Denominator includes counties with 
plan enrollment in 2001, 2002, and/or 2003.  The numerator is counties lacking one or more plans that served the it  for all 3 years.
Figure 8
 
Greater volatility of private plans.  A less-
studied concern about private plans is their 
stability in sparsely-populated areas.  The 
recent “pull-outs” of managed care plans from 
Medicare have demonstrated that continuity 
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matters to beneficiaries.28  To assess whether private plan participation is more or less volatile in 
Medicare, this study examined patterns of plan participation in counties with some enrollment in 
private plans (HMOs, private fee-for-service plans, etc.) in the years 2001, 2002 and/or 2003.  It 
found that, even in rural areas that private plans have opted to serve, plan participation was more 
volatile than it was in urban areas.  Rural beneficiaries who had access to a private plan during 
this period were four times more likely to experience plan instability, meaning that there was no 
private plan that stayed in their county for the entire period (24 versus 6%) (Figure 8).29  In five 
predominantly rural states, not one private 
plan came and participated in Medicare for all 
of the 2001-03 period.  These states are 
Alaska, Maine, Montana, South Dakota and 
Vermont.  In addition, no rural areas in 
Delaware, New Hampshire and South 
Caroline had stable access to private plans.  In 
rural areas, nearly half of those experiencing 
this volatility had lost access to plans, whereas 
in urban areas, an equal proportion of 
beneficiaries had gained and lost access to 
private health plans (Figure 9).  
Causes of Volatility In Areas With 
Private Plans But Without Stable Plans
Percent of Medicare Beneficiaries In Counties That Had Enrollment In 
Private Plans But No Stable Plan From 2001-2003
33%
13%
33%
39%
33%
48%
Urban Rural
Lost
Plan(s)
Gained
Plan(s)
Different
Plans Each
Year
Source:  Analysis of 2001-03 CMS Quarterly Plan Data for June 2001, 2002 and 2002.  Denominator is all eligible Medicare
beneficiaries in counties that had enrollment in private plans in 2001, 2001 and/or 2003 but did not have a single plan that was in 
that county for all three years.  
Figure 9
 
These findings suggest that even if private plans emerge to deliver the prescription drug benefit 
in rural areas, beneficiaries in those areas could be forced to change plans more often due to 
private plan turnover.  This may cause problems beyond inconvenience.  Since the proposals 
would provide insurers with the ability to use a formulary and vary cost sharing, the amount that 
a rural senior pays for the same prescription could change from year to year.   
 
Exacerbates benefit inequity.  Both proposals would continue the current system that allows 
Medicare overpayments to private plans that deliver the core Medicare benefits to be used to 
subsidize extra benefits for enrollees.  In addition, the legislation would increase private plan 
payment rates which are currently paid about 4 percent more than it would cost to deliver the 
same services in the traditional program.30  Medicare experts have suggested that private plans 
like PPOs would have to be paid well above the average traditional Medicare costs to 
participate31 – meaning that increased use of private plans in Medicare could worsen rather than 
strengthen Medicare’s long-run financing outlook.  CBO estimates that private plan payment 
increases in the Medicare bills would cost from $6 to $8 billion from 2004 to 2013 (excluding 
the House’s 2010 “premium support” policy and Senate 2009 PPO demonstration).  These 
payment changes would increase enrollment from 8 to 11 percent, under CBO assumptions.32  
However, the other official estimator of Medicare costs, the Office of the Actuary at the Centers 
for Medicare and Medicaid Services (CMS), projects that, without the House premium support 
provision, private plan enrollment could reach 43 percent by 2010. 33  It has not released its 
estimates of the cost associated with this much-higher enrollment projected, but if the Medicare 
cost increase is commensurate with the coverage increase, costs could be up to 4 times higher, or 
$32 billion over the period.  This is in addition to the relief that private plans would get with the 
passage of a Medicare-subsidized prescription drug benefit.   
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Since private plan rates are already higher 
than the cost of traditional Medicare in rural 
areas, it is not clear that these extra payments, 
and, thus, subsidized benefits, would benefit 
rural Medicare beneficiaries.  However, the 
size of this investment is large enough that it 
could be reallocated to improve Medicare’s 
preventive service coverage or start down a 
path of providing catastrophic cost protection 
in Medicare for all of its beneficiaries, 
irrespective of plan choice.  Maintaining 
current payment levels for private plans would 
also allow conferees to eliminate the increases 
in beneficiary cost sharing proposed in both 
bills.34  In each bill, the cost of the private plan payment increase is about the same as the savings 
achieved by these policies. These cost sharing increases would disproportionately affect rural 
beneficiaries given their lower average income and already-higher out-of-pocket burden.  
Compared to urban beneficiaries, rural beneficiaries’ out-of-pocket spending on Medicare-
covered provider services, outpatient hospital and inpatient hospital care is 10, 30 and 80 percent 
higher respectively (Figure 10).   
Rural Medicare Beneficiaries 
Pay More Out-of-Pocket for 
Medicare Cost Sharing
Average Out-of-Pocket Spending for Selected 
Services, 2000
$400
$71 $57
$445
$92 $103
Physicians* Outpatient
Hospital
Inpatient
Hospital
Urban Rural
Source:  Analysis of 2000 Medicare Current Beneficiary Survey; excludes institutionalized beneficiaries. 
* Includes other Part B providers
Figure 10
 
Penalizes those staying in traditional Medicare.  As with any increase in Medicare Part B 
costs, all beneficiaries would share in the private plan cost increases through higher premiums.  
This means that, under both proposals, rural beneficiaries would pay higher premiums even if 
they lack access to the extra benefits offered by private plans, which are subsidized, in part, 
through those premiums.  The Senate bill, in addition to the rate increases, would authorize a $6 
billion demonstration to promote participation of PPOs.35  The cost of this, too, would be borne 
in part by beneficiaries in the traditional program who might lack access to this option.     
 
The House “premium support” provision would, beginning in 2010, change the structure of 
Medicare premiums.  The government would, in areas where private plans participate, cap its 
liability for costs, even for traditional Medicare.  This means that if two or more private plans 
were to come to a rural area, then beneficiaries’ premiums for staying in traditional Medicare 
could go up, even if they do not join a private plan.36  The impact of this provision is quite 
uncertain.  CBO projects that it could both increase and decrease premiums in traditional 
Medicare under different circumstances.37  The CMS Actuaries put an upper bound on the 
potential effect, suggesting that the proposal could raise Medicare’s Part B premiums by 25 
percent.38  This would translate into about a $24 per month increase in the Medicare premium if 
the proposal were fully implemented in 2010.  One analysis found that this increase, coupled 
with the Part B deductible increase, would eliminate the average Social Security cost-of-living 
adjustment when fully effective.39  Although private plans are less likely to go to rural areas, in 
2003, about 1.4 million rural beneficiaries lived in areas with access to two or more private plans 
which would trigger premium support.40  The premium impact of premium support would 
disproportionately affect rural seniors, given their lower average Social Security checks and 
higher average out-of-pocket spending on health care.41    
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DISCUSSION AND RECOMMENDATIONS 
 
Congress is on the verge of enacting a Medicare prescription drug benefit – an historic 
opportunity and challenge.  Both the House and Senate bills would invest about $400 billion over 
10 years in a prescription drug benefit that has features that would help all beneficiaries as well 
as rural beneficiaries.  For example, both bills provide some level of protection against excessive 
out-of-pocket drug costs and ensure convenient access to pharmacies.  The proposals contain 
various provisions to improve Medicare’s care coordination, preventive benefits, and payment 
systems for rural health care providers.  And some provisions would make prescription drugs 
more affordable for nonelderly Americans.     
 
That said, the Medicare proposals currently being considered include provisions that would not 
lessen the current disadvantages faced by rural beneficiaries and, in some cases, could exacerbate 
them.  Rural beneficiaries have lower income and thus a greater proportion would be excluded 
from the Senate Medicare benefit that denies coverage to Medicare-Medicaid dual eligibles.  The 
greater proportion of near-poor rural beneficiaries would be left unprotected from the “gap” in 
the House plan.  In addition to the problems associated with having lower income, rural 
beneficiaries are more likely to have chronic illnesses like arthritis or cancer.  Without a defined 
benefit, private insurers could vary the cost sharing to discourage enrollment of less healthy and 
more expensive beneficiaries who disproportionately live in rural areas.  For the same reasons, 
the insurer-set premiums for drug coverage could be higher in rural areas.   
 
The prescription drug benefit’s delivery system in both plans would be part of a larger effort to 
promote the use of private health insurance in Medicare.  The drug benefit would be delivered 
exclusively by private insurers in the House bill.  If past is prologue, it would be a challenge 
attracting private plans to all rural areas.  Even if the proposal succeeded, this study suggests that 
rural beneficiaries would experience less continuity and greater turnover in plans:  4 times the 
proportion of rural beneficiaries who had some access to private plans in Medicare did not have a 
single plan that stayed for three consecutive years.  In addition, legislation would significantly 
increase payments to private plans, exacerbating the differential between urban and rural 
beneficiaries’ access to Medicare-funded supplemental benefits.  Not only would rural seniors 
generally have less access to private plans’ extra benefits, the proposed payment rate increases 
would result in higher premiums for rural beneficiaries.  Finally, the House plan’s provision that 
would cap Medicare’s contribution to the traditional program could result in premium increases 
that would be harder to afford for lower-income rural beneficiaries.   
 
As policy makers move toward final passage of this legislation, a number of changes could be 
made to ensure that it protects and strengthens Medicare for rural beneficiaries.  First, given the 
age, health, and income profile of rural beneficiaries, stronger protections for low-income and 
sicker beneficiaries should be considered.  Making the Medicare prescription drug benefit 
accessible to all beneficiaries, as is done in the House bill, would help the larger proportion of 
rural beneficiaries who are enrolled in Medicaid and thus disqualified under the Senate plan.  
Indeed, this change is essential to making this drug benefit universal, meaning that all 
beneficiaries, irrespective of where they live or their financial circumstances, would be eligible 
for it.42  While the Senate bill is weaker in its treatment of the lowest-income seniors, it would 
provide more generous prescription drug subsidies for those with income above Medicaid 
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eligibility limits.  Specifically, it would eliminate both the Medicare coverage gap prior to 
reaching the catastrophic limit for low-income beneficiaries and the “assets test” for certain types 
of assistance, increasing the number of seniors who qualify for help.  Yet, to truly help low-
income rural beneficiaries, the final legislation would need to improve upon the Senate bill’s 
protections as well, since its average out-of-pocket drug costs would consume 15 percent of 
certain low-income beneficiaries’ income, according to a recent study.43    
 
Along the same lines, the profile of rural beneficiaries shows that they tend to be sicker and thus 
would especially benefit from a defined prescription drug benefit.  Both proposals would provide 
private insurers wide latitude in setting the cost sharing generally and across different types of 
drugs.  This could lead to sicker beneficiaries paying higher cost sharing or being discouraged 
from enrolling in a plan (adverse selection).  For example, a private plan’s coinsurance could be 
set low (e.g., 10%) for initial costs but could increase as costs rise (e.g., 80% for expenditures 
just before the coverage gap).  This could be addressed by having the standard benefits in both 
bills serve as the upper limit rather than the average target for cost sharing.44  In addition, private 
insurers would be permitted to charge very high copays for expensive but rare medications and 
slightly lower than average copays on less expensive but more commonly used drug.  The bills 
could require that the coinsurance for covered drugs be the same across all types of drugs.45  The 
prescription drug premiums as well as the cost sharing would be set by private insurers under the 
bills.  Having the government pay for full geographic cost variation (not just price differences) 
would help insulate rural beneficiaries from paying relatively higher premiums due to their 
greater need.  Limits could also be placed on both the variation in drug premiums charged to 
beneficiaries across the nation as well as annual increases in premiums to provide greater 
predictability for rural seniors who typically pay Medicare premiums from lower-than-average, 
fixed Social Security checks.   
 
Second, Congress should consider a more stable delivery system for the prescription drug 
benefit.  The experience of the Medicare+Choice program promises greater private plan scarcity 
and volatility in rural versus urban areas.  This suggests that rural beneficiaries should be given a 
choice of receiving the drug benefit through private insurers or a stable, non-risk bearing private 
plan (e.g., pharmaceutical benefit manager).  This would mitigate against the access problems 
that could result from frequent changes in drug coverage for rural seniors, which would likely 
occur under both bills.  Short of providing this choice, the legislation could specify the minimum 
size of service areas for prescription drug plans, improving the odds that private plans serve rural 
America. 46  For example, the legislation could require that private drug insurers serve an area 
with no fewer than one-tenth of the Medicare population.47  In addition, having a “fallback” 
system of non-risk bearing plans in place would mitigate against possible access problems that 
could occur in the event that private plans do not serve rural areas.  While the Senate bill 
contains such a fallback plan, it could be strengthened by allowing organizations that provide 
fallback coverage to operate under the same rules as private plans (e.g., having a multi-year 
contract with Medicare).  The legislation could, as well, allow a fallback option to stay in areas 
that are susceptible to under-service, even if a private plan returns, given the greater likelihood 
that the return is temporary.  These policy changes would lessen the volatility of prescription 
drug coverage that is likely to occur in rural America under these proposals.  
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Third, Medicare subsidies for supplemental benefits should be allocated equitably so that all 
beneficiaries, regardless of where they live or which delivery system they choose, receive the 
same level of Medicare assistance.  Rather than exacerbating the benefit inequities in the current 
Medicare managed care system, the final legislation could use the $8 to $12 billion in funding 
for the PPO demonstration and private plan rate increases to improve benefits for all 
beneficiaries.  For example, benefits recommended by the U.S. Preventive Services Task Force 
that are not now covered by Medicare48 probably could be added to the program for the cost of 
the private plan payment increases.  New payment systems for chronic disease management, care 
coordination for high-cost cases, and incentives for quality could be tested or funded with this 
investment.  And, a catastrophic limit on all Medicare cost sharing, not just for prescription 
drugs, could be phased in for all Medicare beneficiaries, not just those in private plans.  
Alternatively, this funding could be used to eliminate the proposed increases in Medicare cost 
sharing.  Rural beneficiaries would be disproportionately affect by these changes given their 
already-higher out-of-pocket spending for Medicare services and lower average income.  For the 
same reasons, the House bill’s premium support proposal, while less likely to be implemented in 
rural areas, would create a greater cost burden on rural versus urban beneficiaries and should be 
reconsidered.   
 
Many of these recommendations are consistent with those suggested by rural health experts and 
others.  A RUPRI Rural Health Panel, recognizing the special needs of rural Medicare 
beneficiaries, emphasized the importance of making the prescription drug benefit affordable, 
especially to low-income beneficiaries.  It also recommended “that premiums charged to rural 
beneficiaries should not vary because they live in rural areas (consistent with historical Medicare 
policy as evidenced by the Part B premiums).”49   The suggestions on improving the stability of 
the prescription drug delivery system echo those of a National Rural Health Association expert 
panel that recommended that the “government should also offer a base (default) plan” to ensure 
affordable access.50  And, on the role of private plans, the Advisory Committee on Rural Health, 
chaired by former Senator Nancy Kassebaum Baker, wrote, “The real policy issue is not about 
getting more managed care plans into rural counties but rather about equity of benefits for rural 
beneficiaries.”51  These policy changes have also been considered in alternative legislation, 
amendments, and by broader aging advocate groups.52  The passage of a Medicare prescription 
drug benefit is, perhaps, more important to rural beneficiaries, given their greater need and lower 
coverage today, but improvements should be made to ensure that the legislation meets its 
promise for these rural Americans. 
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APPENDIX 
Medicare’s Rural Beneficiaries By State, 2003 
 
Rural Percent of Rural Percent of 
Beneficiaries All Beneficiaries Beneficiaries All Beneficiaries
Alabama 229,014 32% Montana 90,268 66%
Alaska 24,657 55% Nebraska 142,621 56%
Arizona 107,501 14% Nevada 38,907 14%
Arkansas 267,822 58% New Hampshire 82,349 45%
California 184,502 4% New Jersey 0%
Colorado 94,181 19% New Mexico 115,753 45%
Connecticut 46,873 9% New York 251,988 9%
Delaware 35,474 29% North Carolina 471,135 39%
District of Columbia 0% North Dakota 50,104 58%
Florida 239,200 8% Ohio 348,538 20%
Georgia 343,892 36% Oklahoma 241,663 45%
Hawaii 49,270 27% Oregon 181,012 34%
Idaho 119,384 65% Pennsylvania 361,974 17%
Illinois 354,033 21% Rhode Island 14,508 8%
Indiana 275,278 31% South Carolina 206,616 33%
Iowa 287,822 60% South Dakota 55,258 60%
Kansas 190,077 49% Tennessee 343,541 38%
Kentucky 369,726 56% Texas 528,938 22%
Louisiana 172,254 27% Utah 65,131 29%
Maine 144,268 62% Vermont 62,287 72%
Maryland 65,730 9% Virginia 287,453 30%
Massachusetts 14,589 1% Washington 179,391 22%
Michigan 295,939 20% West Virginia 212,475 59%
Minnesota 266,826 39% Wisconsin 311,605 38%
Mississippi 307,501 68% Wyoming 48,459 69%
Missouri 333,972 37% U.S. 9,511,759 23%
 
Source: Calculated from data from the Centers for Medicare and Medicaid Services.  Note: these data 
are from the eligibility files for the managed care plan penetration.  The latest official state and county 
counts of Medicare beneficiaries are for 2001.     
 
Note: A study from Families USA (May 2003) found a much larger number or rural beneficiaries in North 
Dakota (68,181) and South Dakota (85,738).   
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Percentage of Urban and Rural Non-Institutionalized Medicare Beneficiaries Who 
Lacked Prescription Drug Coverage, 2000 
 
 Urban Rural 
Total 18% 31% 
Age 
 < 65 
65-84 
85 + 
 
 
17% 
18% 
23% 
 
 
26% 
31% 
37% 
Health Status 
Fair / Poor 
 
16% 
 
 
28% 
Self-Reported Chronic 
Illness 
Heart condition 
Cancer 
Arthritis 
Chronic lung disease 
Mental disorder 
Alzheimer’s disease 
Diabetes 
Hypertension 
Stroke 
 
 
 
16% 
17% 
17% 
13% 
17% 
16% 
13% 
16% 
17% 
 
 
25% 
30% 
29% 
23% 
26% 
29% 
24% 
27% 
31% 
 
Source:  Authors’ analysis of the Medicare Current Beneficiary Survey 2000.  Does not include 
institutionalized persons.  
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METHODOLOGY 
 
Data from the 2000 Medicare Current Beneficiary (MCBS) Cost and Use file were used to study 
prescription drug coverage, expenditures and use across urban and rural residence.  The MCBS is 
a longitudinal panel survey of a representative national sample of the Medicare population 
conducted under the auspices of the Centers for Medicare and Medicaid Services.  Begun in the 
fall of 1991, over 12,000 Medicare beneficiaries are interviewed three times a year using 
computer assisted personal interviewing.  MCBS interviewers collect extensive information on 
individuals' use and expenditures for health services including source of payment, as well as 
information on health insurance, access to care, health and functional status, socioeconomic 
status, and demographic characteristics.  Prescription drug utilization data in the MCBS are 
based on self-reports of each prescription filled and refilled during the year.  To assure accurate 
recall, respondents are asked to keep bill records and prescription containers to show 
interviewers during the thrice-yearly interviews. 
 
Our sample consisted of disabled and aged Medicare beneficiaries living in the community.  We 
excluded persons who lived in institutional facilities throughout the entire year because drug use 
data for this population are not available. We categorized the sample as living in rural or non-
rural areas as defined by the MCBS, which takes this information from the administrative 
records of the Centers for Medicare and Medicaid Services.  The MCBS defines “rural” as 
counties that do not lie within a Metropolitan Statistical Area (MSA). By this definition, rural 
areas include counties that are contiguous to urban centers but are not part of the MSA. Our 
unweighted samples sizes are: 3,361 beneficiaries in rural areas and 8,616 beneficiaries in 
nonrural areas.  
 
The data for the analysis of the stability of private plan participation in Medicare came from the 
Medicare managed care market penetration state/county/plan files from June 2001, 2002 and 
2003.53  Counties were considered rural if they were not classified as part of an MSA according 
to the OMB/ Census Bureau.54  The analyses excluded the territories, a small number of counties 
with incomplete data, and enrollment in the United Mine Workers Association plan (due to its 
distinction from other types of Medicare plans).  “Plan” throughout the study means one type of 
benefit offering offered by an organization; the same organization can offer multiple plans.  
Because the authors were interested in access within counties that have had active private plan 
participation, only those counties where there was minimum enrollment (11 enrollees) in the last 
three years were included.55  Each county was placed into one of four categories: (1) stable 
plan(s): the county had at least one plan that has served the county for all three years; (2) 
changing plans: the county had enrollment in private plans in each year, but no single plan stayed 
for all three years; (3) gained plan(s): the county did not have an active plan in 2001 and/or 2002 
and gained one or more in 2002 or 2003; and (4) lost plan(s): the county had a plan in 2001 
and/or 2002 and lost it in 2002 or 2003.  The number of eligible Medicare beneficiaries in each 
county for 2003 was summed by plan category and tabulated separately for rural and urban 
counties to produce the results described in this study.   
 
The analysis was done twice, using both the broadest and narrowest types of Medicare private 
plans to assess whether the results differed.  Typically, analysts only use the HMO, PPO and 
provider sponsored organizations (PSOs) (coordinated care plans) in assessing the program.  
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This is because these types of plans generally meet the traditional definition of managed care 
plans and are paid for under the rules of the Medicare+Choice program.  However, recently, the 
emergence of private fee-for-service plans and, to a lesser extent, the PPO demonstration plans 
has significantly increased access to private plans in rural areas.  Thus, to be conservative, the 
results highlighted in this paper use the broadest definition of private plans, including any type of 
private plan or demonstration, although the results using the narrower group of managed care 
plans were consistent.   
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